Education
About Us
Working with TipRanks
Follow Us
Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
ZBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.83 - $26.25
Previous CloseN/A
Volume96.53K
Average Volume (3M)264.56K
Market Cap
$931.48M
Enterprise Value$133.40M
Total Cash (Recent Filing)$273.28M
Total Debt (Recent Filing)$1.01M
Price to Earnings (P/E)―
Beta0.73
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.90
Shares Outstanding42,110,313
10 Day Avg. Volume281,515
30 Day Avg. Volume264,557
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue8.89
Enterprise Value/Gross Profit8.92
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$33.25Price Target Upside58.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe pivotal Phase 3 INDIGO trial for obexelimab in IgG4-related disease has completed enrollment, with topline results anticipated, highlighting continued progress.
Funding AgreementZenas BioPharma has entered into a funding agreement with Royalty Pharma providing up to $300M in cash.
Market EndorsementThe agreement with Royalty Pharma indicates a strong endorsement of Zenas BioPharma's potential in the market.
Bears Say
Clinical Data LimitationsThe lack of clinical data in this indication tempers expectations for the upcoming 12-week MoonStone readout.
Operational ChallengesThe company has indicated that a partnership will likely be needed to advance the MS program, suggesting potential challenges in moving forward independently.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $5.83 and its highest was $26.25 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $931.48M.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on May 15, 2025. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.134 by $0.334.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 42,110,313 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.134. Following the earnings report the stock price went up 6.711%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
Zenas BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.25 (58.71% Upside)
$33.25 (58.71% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.05%
12-Months-Change
Fundamentals
Return on Equity
-88.40%
Trailing 12-Months
Asset Growth
46.58%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
ZBIO Stock 12 Month Forecast
Average Price Target
$33.25
▲(58.71% Upside)
Technical Analysis
Ownership Overview
17.70% Insiders
17.24% Mutual Funds
55.96% Other Institutional Investors
5.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---